Analysts Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Target Price at $43.33

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has been given an average recommendation of “Moderate Buy” by the ten ratings firms that are presently covering the company, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $43.33.

Several equities analysts have commented on ARWR shares. HC Wainwright reissued a “buy” rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Thursday, January 23rd. Piper Sandler lowered their price objective on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 27th. Chardan Capital restated a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday. StockNews.com raised Arrowhead Pharmaceuticals to a “sell” rating in a research note on Friday, December 20th. Finally, Sanford C. Bernstein dropped their price objective on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating on the stock in a research note on Friday, November 29th.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, Director William D. Waddill sold 3,748 shares of the business’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $21.90, for a total transaction of $82,081.20. Following the sale, the director now directly owns 44,125 shares of the company’s stock, valued at $966,337.50. The trade was a 7.83 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Christopher Richard Anzalone sold 11,520 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $19.05, for a total value of $219,456.00. Following the completion of the sale, the chief executive officer now owns 3,764,252 shares of the company’s stock, valued at $71,709,000.60. The trade was a 0.31 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 147,432 shares of company stock worth $2,957,986 in the last three months. 4.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ARWR. State Street Corp boosted its holdings in shares of Arrowhead Pharmaceuticals by 8.8% during the third quarter. State Street Corp now owns 6,354,331 shares of the biotechnology company’s stock worth $123,083,000 after purchasing an additional 516,569 shares during the period. Assenagon Asset Management S.A. boosted its stake in shares of Arrowhead Pharmaceuticals by 232.5% during the 3rd quarter. Assenagon Asset Management S.A. now owns 293,083 shares of the biotechnology company’s stock valued at $5,677,000 after buying an additional 204,933 shares during the period. abrdn plc grew its holdings in shares of Arrowhead Pharmaceuticals by 61.3% during the 3rd quarter. abrdn plc now owns 401,146 shares of the biotechnology company’s stock valued at $7,770,000 after acquiring an additional 152,476 shares in the last quarter. Edgestream Partners L.P. acquired a new position in shares of Arrowhead Pharmaceuticals in the fourth quarter worth $2,264,000. Finally, Fisher Asset Management LLC increased its stake in shares of Arrowhead Pharmaceuticals by 941.0% in the third quarter. Fisher Asset Management LLC now owns 122,260 shares of the biotechnology company’s stock worth $2,368,000 after acquiring an additional 110,516 shares during the last quarter. 62.61% of the stock is owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Stock Down 5.2 %

ARWR opened at $18.89 on Wednesday. The stock’s 50 day moving average price is $20.23 and its 200 day moving average price is $21.25. The company has a debt-to-equity ratio of 2.06, a current ratio of 6.74 and a quick ratio of 6.74. The stock has a market cap of $2.36 billion, a P/E ratio of -3.76 and a beta of 0.95. Arrowhead Pharmaceuticals has a 12 month low of $17.05 and a 12 month high of $36.72.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97). As a group, research analysts predict that Arrowhead Pharmaceuticals will post -3.4 earnings per share for the current year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.